TY - JOUR
T1 - Cognitive impairment in fibromyalgia
T2 - A meta-analysis of case-control studies
AU - Wu, Yu Lin
AU - Huang, Chun Jen
AU - Fang, Su Chen
AU - Ko, Ling Hsin
AU - Tsai, Pei Shan
N1 - Publisher Copyright:
© Lippincott Williams & Wilkins.
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Objective Cognitive dysfunction has been reported in individuals with fibromyalgia. However, findings regarding cognitive function examined using neuropsychological tests have been inconsistent. The aim of the study was to determine domain-specific cognitive impairment in patients with fibromyalgia compared with healthy controls. Methods We conducted a meta-analysis that systematically searched six databases (PubMed, Ovid MEDLINE, Embase, CINAHL, PsycINFO, and Web of Science) for articles published before September 2017. Results Twenty-three case-control studies with a total of 2096 participants were included in the meta-analysis. Cognitive function was significantly lower (g = 0.87, 95% confidence interval [CI] = 0.60-1.15) in individuals with fibromyalgia than in healthy controls. Large effect sizes were found in learning/memory and attention/psychomotor speed (g = 0.94, p =.013; g = 1.22, p <.001, respectively); medium effect sizes were reported in executive function and working memory (g = 0.72, p <.001; g = 0.75, p <.001, respectively). Depression and anxiety scores were associated with the effect size of group differences in cognitive function (B = 0.11, p <.001, 95% CI = 0.09-0.13; B = 0.02, p <.001, 95% CI = 0.01-0.02, respectively). Conclusions Cognitive impairment across different cognitive domains was found in individuals with fibromyalgia compared with healthy controls. Mood states (depression and anxiety) may explain the heterogeneity across studies.
AB - Objective Cognitive dysfunction has been reported in individuals with fibromyalgia. However, findings regarding cognitive function examined using neuropsychological tests have been inconsistent. The aim of the study was to determine domain-specific cognitive impairment in patients with fibromyalgia compared with healthy controls. Methods We conducted a meta-analysis that systematically searched six databases (PubMed, Ovid MEDLINE, Embase, CINAHL, PsycINFO, and Web of Science) for articles published before September 2017. Results Twenty-three case-control studies with a total of 2096 participants were included in the meta-analysis. Cognitive function was significantly lower (g = 0.87, 95% confidence interval [CI] = 0.60-1.15) in individuals with fibromyalgia than in healthy controls. Large effect sizes were found in learning/memory and attention/psychomotor speed (g = 0.94, p =.013; g = 1.22, p <.001, respectively); medium effect sizes were reported in executive function and working memory (g = 0.72, p <.001; g = 0.75, p <.001, respectively). Depression and anxiety scores were associated with the effect size of group differences in cognitive function (B = 0.11, p <.001, 95% CI = 0.09-0.13; B = 0.02, p <.001, 95% CI = 0.01-0.02, respectively). Conclusions Cognitive impairment across different cognitive domains was found in individuals with fibromyalgia compared with healthy controls. Mood states (depression and anxiety) may explain the heterogeneity across studies.
KW - ACR = American College of Rheumatology
KW - ACT = Auditory Consonant Trigram
KW - BAI = Beck Anxiety Inventory
KW - BDI = Beck Depression Inventory
KW - BSI = Brief Symptom Inventory
KW - Cognitive function
KW - Fibromyalgia
KW - Meta-analysis
KW - Pain
UR - http://www.scopus.com/inward/record.url?scp=85048710087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048710087&partnerID=8YFLogxK
U2 - 10.1097/PSY.0000000000000575
DO - 10.1097/PSY.0000000000000575
M3 - Review article
AN - SCOPUS:85048710087
SN - 0033-3174
VL - 80
SP - 432
EP - 438
JO - Psychosomatic Medicine
JF - Psychosomatic Medicine
IS - 5
ER -